guest ::
| Home > Publications database > NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. > print |
| Home > Publications database > NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. > print |
| 001 | 163955 | ||
| 005 | 20240229123201.0 | ||
| 024 | 7 | _ | |a 10.1038/s41392-020-00311-7 |2 doi |
| 024 | 7 | _ | |a pmid:33028824 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC7539288 |2 pmc |
| 024 | 7 | _ | |a 2059-3635 |2 ISSN |
| 024 | 7 | _ | |a 2095-9907 |2 ISSN |
| 024 | 7 | _ | |a altmetric:91942246 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-02168 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Xie, Na |b 0 |
| 245 | _ | _ | |a NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. |
| 260 | _ | _ | |a London |c 2020 |b Macmillan Publishers, part of Springer Nature |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1602485306_26677 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #LA:E055# |
| 520 | _ | _ | |a Nicotinamide adenine dinucleotide (NAD+) and its metabolites function as critical regulators to maintain physiologic processes, enabling the plastic cells to adapt to environmental changes including nutrient perturbation, genotoxic factors, circadian disorder, infection, inflammation and xenobiotics. These effects are mainly achieved by the driving effect of NAD+ on metabolic pathways as enzyme cofactors transferring hydrogen in oxidation-reduction reactions. Besides, multiple NAD+-dependent enzymes are involved in physiology either by post-synthesis chemical modification of DNA, RNA and proteins, or releasing second messenger cyclic ADP-ribose (cADPR) and NAADP+. Prolonged disequilibrium of NAD+ metabolism disturbs the physiological functions, resulting in diseases including metabolic diseases, cancer, aging and neurodegeneration disorder. In this review, we summarize recent advances in our understanding of the molecular mechanisms of NAD+-regulated physiological responses to stresses, the contribution of NAD+ deficiency to various diseases via manipulating cellular communication networks and the potential new avenues for therapeutic intervention. |
| 536 | _ | _ | |a 315 - Imaging and radiooncology (POF3-315) |0 G:(DE-HGF)POF3-315 |c POF3-315 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Zhang, Lu |b 1 |
| 700 | 1 | _ | |a Gao, Wei |b 2 |
| 700 | 1 | _ | |a Huang, Canhua |0 0000-0003-2247-7750 |b 3 |
| 700 | 1 | _ | |a Huber, Peter Ernst |0 P:(DE-He78)3291aaac20f3d603d96744c1f0890028 |b 4 |u dkfz |
| 700 | 1 | _ | |a Zhou, Xiaobo |b 5 |
| 700 | 1 | _ | |a Li, Changlong |b 6 |
| 700 | 1 | _ | |a Shen, Guobo |b 7 |
| 700 | 1 | _ | |a Zou, Bingwen |0 P:(DE-He78)288563599778a46193872ab022a9ce0f |b 8 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1038/s41392-020-00311-7 |g Vol. 5, no. 1, p. 227 |0 PERI:(DE-600)2886872-9 |n 1 |p 227 |t Signal transduction and targeted therapy |v 5 |y 2020 |x 2059-3635 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:163955 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)3291aaac20f3d603d96744c1f0890028 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)288563599778a46193872ab022a9ce0f |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-315 |2 G:(DE-HGF)POF3-300 |v Imaging and radiooncology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b SIGNAL TRANSDUCT TAR : 2018 |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-01-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2020-01-10 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2020-01-10 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2020-01-10 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b SIGNAL TRANSDUCT TAR : 2018 |d 2020-01-10 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |f 2020-01-10 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2020-01-10 |
| 920 | 1 | _ | |0 I:(DE-He78)E055-20160331 |k E055 |l E055 KKE Translationale Radioonkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E055-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|